Latest news

• First oral antiviral drug for COVID-19 reviewed by Health Canada

  Hopes for an effective oral antiviral drug against SARS-CoV-2 have been raised after Merck &Co announced that Health Canada will perform a rolling review of data of its drug, ... An oral antiviral drug is seen by many as an essential part of an effective

• Pardes Biosciences, backed by Gilead and Foresite, goes public to advance lead COVID-19 antiviral drug

  Pardes’ lead oral antiviral drug candidate is designed to inhibit the main protease of SARS-CoV-2. ... PBI-045 – Pardes’ lead oral antiviral drug candidate – is designed to inhibit the main protease (Mpro) of SARS-CoV-2, the virus which causes

• Merck & Co, Ridgeback Biotherapeutics’ COVID-19 drug shows early promise

  Merck &Co – known as MSD outside the US and Canada – and Ridgeback Therapeutics have revealed early promising data for their oral COVID-19 antiviral drug molnupiravir. ... At a time where there is unmet need for antiviral treatments against SARS-CoV-2

• Roche taps local expertise for hep C drug in China

  The two companies will share responsibility for clinical development and commercialisation of the drug under the deal, which also includes a royalty stream. ... Therapy for HCV relies on the use of interferon-alpha in combination - such as Roche's own